Drug intelligence / Profile preview

HL317

Development stage: Preclinical
Lead developer: Hanlim Pharm. Co., Ltd.
Modality: Small Molecules

Overview

HL317 is a small molecule new chemical entity (NCE) being developed by Hanlim Pharmaceuticals for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). As of early 2026, the drug is in the pre-clinical stage of development. While specific details regarding its molecular target and pharmacological mechanism of action have not been publicly disclosed by the developer, it is categorized within their discovery pipeline for neuropsychiatric conditions. The candidate represents Hanlim's efforts to expand its portfolio into central nervous system (CNS) disorders using small molecule discovery platforms.

Beyond the preview

Go deeper on HL317.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HL317.

Explore the full profile